VitaSpring Biomedical Co. Ltd
VitaSpring Biomedical Co. Ltd., a development-stage biomedical company, engages in the research, development, and commercialization of wellness and healthy lifestyle products. The company focuses on the development of cell-based medical technologies for use in regenerative medicine, preventive health care, beauty, and anti-aging applications. It is also involved in the development of cell medicin… Read more
Market Cap & Net Worth: VitaSpring Biomedical Co. Ltd (VSBC)
VitaSpring Biomedical Co. Ltd (PINK:VSBC) has a market capitalization of $207.03 Million ($207.03 Million) as of March 18, 2026. Listed on the PINK stock exchange, this USA-based company holds position #18350 globally and #6845 in its home market, demonstrating a 0.00% increase in market value over the past year.
Market capitalization, also known as net worth in stock markets, is calculated by multiplying VitaSpring Biomedical Co. Ltd's stock price $1.00 by its total outstanding shares 207030030 (207.03 Million).
VitaSpring Biomedical Co. Ltd Market Cap History: 2019 to 2025
VitaSpring Biomedical Co. Ltd's market capitalization history from 2019 to 2025. Data shows change from $434.76 Million to $207.03 Million (-12.85% CAGR).
VitaSpring Biomedical Co. Ltd Market Cap to Earnings & Revenue Ratios Timeline
This chart shows how VitaSpring Biomedical Co. Ltd's valuation ratios have evolved. The Price to Sales (P/S) ratio compares market cap to revenue, while the Price to Earnings (P/E) ratio compares market cap to net income. Lower values may indicate a more undervalued company relative to its financial performance.
Latest Price to Sales (P/S) Ratio
531.11x
VitaSpring Biomedical Co. Ltd's market cap is 531.11 times its annual revenue
1728.56x
Lower than industry averageLatest Price to Earnings (P/E) Ratio
2358.57x
VitaSpring Biomedical Co. Ltd's market cap is 2358.57 times its annual earnings
0.11x
Higher than industry averageWhat These Ratios Tell Investors:
- Price to Sales (P/S) Ratio: Shows how much investors are paying for each dollar of the company's sales. Lower P/S ratios may indicate undervaluation.
- Price to Earnings (P/E) Ratio: Shows how much investors are paying for each dollar of the company's earnings. This is one of the most common valuation metrics.
- Trends in these ratios over time can indicate changing investor sentiment about the company's future growth prospects.
- Industry comparison provides context for whether the company is valued higher or lower than peers.
| Year | Market Cap (USD) | Revenue (USD) | Net Income (USD) | P/S Ratio | P/E Ratio |
|---|---|---|---|---|---|
| 2019 | $434.76 Million | $17.18K | -$22.40K | 25306.35x | N/A |
| 2020 | $2.48 Billion | $15.14K | $6.92K | 164092.49x | 359063.50x |
| 2021 | $4.04 Billion | $248.20K | -$425.38K | 16265.37x | N/A |
| 2022 | $2.98 Billion | $5.61 Million | $1.26 Million | 531.11x | 2358.57x |
Competitor Companies of VSBC by Market Capitalization
Companies near VitaSpring Biomedical Co. Ltd in the global market cap rankings as of March 18, 2026.
Key companies related to VitaSpring Biomedical Co. Ltd by market ranking:
- Vertex Pharmaceuticals Inc (NASDAQ:VRTX): Ranked #162 globally with a market cap of $117.09 Billion USD.
- Regeneron Pharmaceuticals Inc (NASDAQ:REGN): Ranked #281 globally with a market cap of $74.80 Billion USD.
- CSL Limited (PINK:CMXHF): Ranked #344 globally with a market cap of $63.46 Billion USD.
- argenx SE (OTCGREY:ARGNF): Ranked #500 globally with a market cap of $42.99 Billion USD.
| Rank | Company | Symbol | Market Cap | Price |
|---|---|---|---|---|
| #162 | Vertex Pharmaceuticals Inc | NASDAQ:VRTX | $117.09 Billion | $462.49 |
| #281 | Regeneron Pharmaceuticals Inc | NASDAQ:REGN | $74.80 Billion | $759.05 |
| #344 | CSL Limited | PINK:CMXHF | $63.46 Billion | $149.87 |
| #500 | argenx SE | OTCGREY:ARGNF | $42.99 Billion | $697.42 |
VitaSpring Biomedical Co. Ltd Historical Marketcap From 2019 to 2025
Between 2019 and today, VitaSpring Biomedical Co. Ltd's market cap moved from $434.76 Million to $ 207.03 Million, with a yearly change of -12.85%.
| Year | Market Cap | Change (%) |
|---|---|---|
| 2025 | $207.03 Million | -93.75% |
| 2024 | $3.31 Billion | 0.00% |
| 2023 | $3.31 Billion | +11.11% |
| 2022 | $2.98 Billion | -26.15% |
| 2021 | $4.04 Billion | +62.50% |
| 2020 | $2.48 Billion | +471.43% |
| 2019 | $434.76 Million | -- |
End of Day Market Cap According to Different Sources
On Mar 18th, 2026 the market cap of VitaSpring Biomedical Co. Ltd was reported to be:
| Source | Market Cap |
|---|---|
| Yahoo Finance | $207.03 Million USD |
| MoneyControl | $207.03 Million USD |
| MarketWatch | $207.03 Million USD |
| marketcap.company | $207.03 Million USD |
| Reuters | $207.03 Million USD |
Market cap values may vary slightly between sources due to differences in calculation methods, timing, and data refresh rates.